An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking.
In retroviral vector-mediated gene transfer, transduction efficiency can be hampered by inhibitory molecules derived from the culture fluid of virus producer cell lines. To remove these inhibitory molecules to enable better gene transduction, we had previously developed a transduction method using a fibronectin fragment-coated vessel (i.e., the RetroNectin-bound virus transduction method). In the present study, we developed a method that combined RetroNectin-bound virus transduction with low-temperature shaking and applied this method in manufacturing autologous retroviral-engineered T cells for adoptive transfer gene therapy in a large-scale closed system. Retroviral vector was preloaded into a RetroNectin-coated bag and incubated at 4°C for 16 h on a reciprocating shaker at 50 rounds per minute. After the supernatant was removed, activated T cells were added to the bag. The bag transduction method has the advantage of increasing transduction efficiency, as simply flipping over the bag during gene transduction facilitates more efficient utilization of the retroviral vector adsorbed on the top and bottom surfaces of the bag. Finally, we performed validation runs of endoribonuclease MazF-modified CD4(+) T cell manufacturing for HIV-1 gene therapy and T cell receptor-modified T cell manufacturing for MAGE-A4 antigen-expressing cancer gene therapy and achieved over 200-fold (≥ 10(10)) and 100-fold (≥ 5 × 10(9)) expansion, respectively. In conclusion, we demonstrated that the large-scale closed transduction system is highly efficient for retroviral vector-based T cell manufacturing for adoptive transfer gene therapy, and this technology is expected to be amenable to automation and improve current clinical gene therapy protocols.
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Katsuyuki
K
Dodo
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Hideto
H
Chono
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Naoki
N
Saito
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Yoshinori
Y
Tanaka
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Kenichi
K
Tahara
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Ikuei
I
Nukaya
Center for Cell and Gene Therapy, Takara Bio Inc. Seta, Otsu, Shiga, Japan.
Junichi
J
Mineno
D000327:Adsorption; D015496:CD4-Positive T-Lymphocytes; D018929:Cell Culture Techniques; D002460:Cell Line; D020099:Coated Materials, Biocompatible; D005353:Fibronectins / Q000737:chemistry*; D015316:Genetic Therapy; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D011401:Promoter Regions, Genetic; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis / Q000235:genetics; D012190:Retroviridae / Q000235:genetics*; D013696:Temperature; D014161:Transduction, Genetic / Q000379:methods*
D020099:Coated Materials, Biocompatible; D005353:Fibronectins; D011948:Receptors, Antigen, T-Cell